{"schema_version":"secwatch.filing_event.v1","accession":"0001628908-23-000014","form_type":"8-K","ticker":"EVH","cik":"0001628908","company_name":"Evolent Health, Inc.","filed_at":"2023-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.920693+00:00","generated_at":"2026-06-19T04:57:35.773474+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Evolent Health Q4 revenue up 54% to $382.4M; new partnerships to add $250M+ in 2024","bullets":["Q4 revenue $382.4M (+54% YoY); net loss $11.3M; Adjusted EBITDA $32.3M (8.4% margin).","Full year 2022 revenue $1,352M (+48.9% YoY); net loss $19.2M; Adjusted EBITDA $106.3M (7.9% margin).","Total Lives on Platform 20.6M as of Dec 31, 2022, up from 17.7M a year ago.","New Performance Suite deal with 5th largest US health insurer for oncology in FL/AZ, expected to drive >$250M revenue in 2024.","New risk-based agreement with large regional health plan within Evolent Care Partners."],"urls":{"canonical":"https://secwatch.observer/filing/0001628908-23-000014","json":"https://secwatch.observer/filing/0001628908-23-000014.json","markdown":"https://secwatch.observer/filing/0001628908-23-000014.md","text":"https://secwatch.observer/filing/0001628908-23-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628908/000162890823000014/0001628908-23-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628908/000162890823000014/evh-20230222.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T04:57:35.773474+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"901e6bf803c81a3a0ece98a37cce513b0996fd25","claim":"Evolent Health, Inc. reported Quarter ended December 31, 2022 results: revenue $382.4 million, net income $11.3 million.","evidence_excerpt":"Quarter ended December 31, 2022: • Revenue of $382.4 million, an increase of $134.1 million, or 54.0%, from the three months ended December 31, 2021. • Net loss attributable to common shareholders of Evolent Health, Inc. of $11.3 million resulting in a net loss margin of (3.0)%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1628908/000162890823000014/0001628908-23-000014-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Quarter ended December 31, 2022"},{"label":"Revenue","value":"$382.4 million"},{"label":"Net income","value":"$11.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"903aa048d1603584fbac6d941d116373457ec9c2","claim":"Evolent Health, Inc. reported Full year ended December 31, 2022 results: revenue $1,352.0 million, net income $19.2 million.","evidence_excerpt":"Full year ended December 31, 2022: • Revenue of $1,352.0 million, an increase of $444.1 million, or 48.9%, from the year ended December 31, 2021. • Net loss attributable to common shareholders of Evolent Health, Inc. of $19.2 million resulting in a net loss margin of (1.4)%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1628908/000162890823000014/0001628908-23-000014-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full year ended December 31, 2022"},{"label":"Revenue","value":"$1,352.0 million"},{"label":"Net income","value":"$19.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}